All In Biotech

Drug Trial Radar · NCT06057610

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

A Phase III Multicenter, Randomized, Open-label, Active-Controlled Study of SHR-A1811 With or Without Pertuzumab Versus Trastuzumab, Pertuzumab and Docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 868 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

868

Actual

Start

Nov 1, 2023

Primary completion

Jul 15, 2026

Study completion Oct 2032

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer

Conditions

  • HER2-PositiveRecurrent or Metastatic Breast Cancer

Interventions

  • SHR-A1811 InjectionDrug

    SHR-A1811 Injection

  • SHR-A1811 Injection ; Pertuzumab InjectionDrug

    SHR-A1811 Injection ; Pertuzumab Injection

  • Trastuzumab Injection;Pertuzumab Injection ; Docetaxel InjectionDrug

    Trastuzumab Injection;Pertuzumab Injection ; Docetaxel Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival by Blinded Independent Central ReviewTime frame: from first dose to disease progression, or death, whichever comes first, up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.